A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Kimberly-Clark plans a $48.7B Kenvue acquisition to drive growth and synergies. Learn the deal's risks, impacts, and KMB's ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...

As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic ...